---
title: 'Frontline treatment of follicular lymphoma: What will it take to change current
  practice?'
date: '2025-01-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39869829/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250128170836&v=2.18.0.post9+e462414
source: Blood
description: Follicular lymphoma is the most common subtype of indolent lymphoma.
  Despite multiple trials over the past decade showing improved progression-free survival
  with new first-line therapeutic strategies -such as anti-CD20 maintenance therapy
  and new glycoengineered anti-CD20 antibodies- no standardized approach has been
  widely adopted in routine clinical practice. Several factors may explain this, including
  the increased incidence of infectious adverse events associated with these ...
disable_comments: true
---
Follicular lymphoma is the most common subtype of indolent lymphoma. Despite multiple trials over the past decade showing improved progression-free survival with new first-line therapeutic strategies -such as anti-CD20 maintenance therapy and new glycoengineered anti-CD20 antibodies- no standardized approach has been widely adopted in routine clinical practice. Several factors may explain this, including the increased incidence of infectious adverse events associated with these ...